Article
Brochure
Executive Resource
Insight Hub
Video
Ext. Publication
Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- Executive & Leadership Coaching
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Sustainability Consulting
- Transaction Advisory
- Trust & Estate
- Valuation
A practical guide to governmental debt types, refundings and reporting risks. How to avoid common audit findings and compliance issues.
Is your transaction a business combination or asset acquisition? Learn how ASC 805 guidance, the screen test and key differences shape reporting.
Texas life sciences in 2025 saw concentrated capital, declining innovation output and earlier‑stage clinical shifts shaping the ecosystem.
HHS has adopted 2 CFR 200 and issued new implementation guidance at 2 CFR 300, replacing 45 CFR 75. Learn how the revised policy affects recipients.
Texas life sciences saw record capital in Q4 2025, even as innovation, early-stage funding and late-phase clinical trials continued to decline.
J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.
Discover 10 surprising ways Texas’ rapid growth and advancements are reshaping industries, driving business innovation and creating new opportunities.
Explore ASC 805’s role in bringing clarity to business combinations — from fair value measurements to goodwill and beyond.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.
Due diligence is a crucial step in any merger and acquisition process. This can be especially challenging for Software-as-a-Service (SaaS) companies.
With an increasing demand for lithium across the energy sector, oilfields may find a common biproduct may hold the key to future growth.
